Related Experiment Videos
Oxazaphosphorine cytostatics: past-present-future. Seventh Cain Memorial Award lecture
1Department of Cancer Research, ASTA Pharma AG, Bielefeld, Federal Republic of Germany.
Abstract:
The development of the oxazaphosphorine cytostatics cyclophosphamide, ifosfamide, and trofosfamide was based on the idea of applying the transport form/active form principle to the highly reactive nitrogen mustard group. A critical analysis and synopsis of the available results and knowledge will include examination of the extent to which the hypotheses on which this concept is based have been confirmed by experimental and clinical findings: 1. Chemical synthesis succeeded in converting the reactive nitrogen mustard into an inactive transport form (latentiation). 2. The requirement that the transport form be enzymatically activated to the active form in the target organ (the cancer cell) has been achieved by a sequence of metabolic reactions. 3. The aim of considerably increasing the therapeutic index of alkylating agents has been achieved by the oxazaphosphorine cytostatics. The greater cancerotoxic selectivity is closely correlated with the cytotoxic specificity of their activated primary metabolites. 4. The cancerotoxic selectivity of oxazaphosphorines was further increased when mesna was introduced as a regional uroprotector. Mesna eliminates the risk of therapy-limiting urotoxic side effects of oxazaphosphorines. With mesna protection, these cytostatics can be given in higher doses with increased safety, and their therapeutic efficacy can be enhanced. 5. Stabilization of the primary oxazaphosphorines, e.g., by attaching 2-mercaptoethanesulfonic acid (mafosfamide), opens up new possibilities in preclinical investigations and in therapy, e.g., for the clonogenic stem cell assay, for in vitro purging in autologous bone marrow transplantation, for regional perfusion of tumors, and, in small doses, for immunomodulation, where appropriate, in conjunction with "biological response modifiers."
Insights
Oxazaphosphorine cytostatics, like cyclophosphamide, were developed using a transport/active form principle. This approach enhances cancer cell targeting and reduces side effects, improving therapeutic efficacy.
Area of Science:
- Oncology
- Pharmacology
- Medicinal Chemistry
Background:
- Nitrogen mustards are highly reactive alkylating agents.
- The transport form/active form principle aims to improve drug delivery and reduce toxicity.
Purpose of the Study:
- To critically analyze the development and efficacy of oxazaphosphorine cytostatics.
- To evaluate the confirmation of hypotheses regarding latentiation, activation, and therapeutic index enhancement.
Main Methods:
- Chemical synthesis for latentiation of nitrogen mustards.
- Metabolic pathway analysis for in vivo activation.
- Clinical evaluation of therapeutic efficacy and toxicity.
Main Results:
- Successful conversion of reactive nitrogen mustard to inactive transport forms.
- Enzymatic activation of transport forms within target cancer cells.
- Significant increase in the therapeutic index of alkylating agents.
- Enhanced cancerotoxic selectivity correlated with activated metabolite specificity.
- Mesna (2-mercaptoethanesulfonic acid) as a uroprotector significantly reduced urotoxic side effects, allowing higher, safer doses and improved efficacy.
Conclusions:
- Oxazaphosphorine cytostatics effectively utilize the transport/active form principle for targeted cancer therapy.
- Mesna uroprotection enhances the safety and efficacy of oxazaphosphorine-based treatments.
- Stabilized oxazaphosphorines offer new therapeutic and preclinical applications, including immunomodulation.